About Us

Leadership

A passionate team with a purpose

We are driven toward invention and healing. Committed to delivering meaningful benefits to the rare and orphan disease community, our dedicated leadership team is the driving force behind our developments. They are constantly inspired by others in the rare disease community, and continually aspire to reach new heights.

John F. Crowley

Chairman of the Board, Chief Executive Officer

John F. Crowley is our Chairman and CEO. John's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children's lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.

John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, "The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children." The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy.

John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame. He is the National Chairman of the Make A Wish Foundation of America and is a founding Board member of the Global Genes Project. John is a Henry Crown Fellow at the Aspen Institute.

Bradley L. Campbell

President and Chief Operating Officer

Bradley L. Campbell is the President and Chief Operating Officer of Amicus and brings over 15 years of experience in the Orphan Drug industry. After joining in 2006, he subsequently took on roles of increasing responsibility throughout the organization. In his current capacity, Mr. Campbell leads the strategy, design and leadership of global commercial operations to support the launch of migalastat, a small molecule personalized medicine in development for the treatment of Fabry Disease. He also oversees Technical Operations, Global Marketing, and Program Management functions.

Prior to Amicus, Mr. Campbell was with Genzyme, serving first as Product Manager for Myozyme® for Pompe disease and later as Business Director of their cardiac gene therapy programs. He has also worked in sales and marketing for Bristol-Myers Squibb, and as a strategy consultant for Marakon Associates.

Mr. Campbell is active with various Boards and philanthropic organizations. He serves as a member of the Board of Directors of Progenics Pharmaceuticals, a public company developing innovative medicines and other products for targeting and treating cancer. He is a member of the BioNJ Board of Directors and is Amicus’ representative to HINJ (Health Care Initiative of New Jersey) Board of Trustees. He is a past President of the National Tay-Sachs and Allied Diseases Association Board of Directors, and currently serves on their Corporate Advisory Council. Bradley received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.

Daphne Quimi

Senior Vice President, Finance and Administration

Daphne Quimi joined Amicus in October 2005 and currently serves as Senior Vice President, Finance and Corporate Controller. She brings experience in public accounting and financial reporting. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at Johnson & Johnson. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A from the Stern School of Business of New York University. She is a certified public accountant in New Jersey and a member of the American Institute of Certified Public Accountants and the Institute of Management Accountants.

David Allsop

Senior Vice President, International

David Allsop joined Amicus in April 2015 as Senior Vice President, International. Mr. Allsop brings international General Management and commercial experience in the biopharmaceutical industry between Biogen Idec and Janssen-Cilag, with extensive operational and strategic leadership in the areas of neurology, autoimmune diseases, hemophilia, gastroenterology, dermatology, and renal. He has successfully launched three blockbuster therapies internationally as well as many other therapies both nationally and internationally. Mr. Allsop has both direct and indirect experience in securing market access and reimbursement in the European Union and international markets.

Prior to joining Amicus, Mr. Allsop was instrumental in building Biogen’s international commercial organization over the last 17 years. He most recently served as Senior Vice President, Europe and Canada, with full responsibility for the business and organization in those territories. While at Biogen he led the successful international launch of several products in the multiple sclerosis franchise, including Avonex®, Tysabri®, Fampyra®, Tecfidera® and Plegridy™ as well as taking responsibility for the hemophilia development organization. Prior to his tenure at Biogen, Mr. Allsop spent 10 years in roles of increasing responsibility at Janssen-Cilag, working in gastroenterology, dermatology and renal, including building and running a number of commercial units and taking responsibility for the Company’s largest brand in the United Kingdom.

Dipal Doshi

Chief Business Officer of Amicus Therapeutics, Inc. and General Manager of Scioderm, Inc.

Dipal Doshi joined Amicus in July 2014 and currently serves as Chief Business Officer of Amicus and General Manager of Scioderm, Inc., an Amicus Company. Prior to joining Amicus, Mr. Doshi founded RStreet Advisors, a healthcare consulting firm through which he advised pharmaceutical, biotech and diagnostics companies on business development, corporate strategy, market and commercial planning activities. From 2008 to 2013, Mr. Doshi was the Senior Vice President and member of the management team at Auven Therapeutics, a 200MM+ global private equity and bio-pharmaceutical development company. Mr. Doshi led or participated in the operations and financing of several biotech and pharmaceutical companies and held Board Observer positions for both Spirogen (acquired by AstraZeneca) and ADC Therapeutics.

From 2005 to 2008, Mr. Doshi was the Head of Corporate Development for Catalent Pharma Solutions (CTLT). Prior to Catalent, Mr. Doshi was a member of Merrill Lynch's Investment Banking Group. During his tenure at Eli Lilly, Mr. Doshi was a member of both the Strategic Marketing team and Lilly Ventures where he developed and led a portfolio company. He was also a sales representative in New York. As a consultant for both Mercer Management Consulting (Oliver Wyman) and Sapient Corporation (Publicis), Mr. Doshi advised healthcare, consumer and technology companies.

Mr. Doshi received a B.A. from Rutgers University and an M.B.A. from The Wharton School of the University of Pennsylvania.

Ellen S. Rosenberg

General Counsel and Corporate Secretary

Ellen S. Rosenberg joined Amicus Therapeutics in February of 2016 as General Counsel and Corporate Secretary. She brings legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions, product launches, risk management, and compliance matters. Prior to joining Amicus, she served as Senior Vice President, Associate General Counsel of Shire Pharmaceuticals. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA.

Ms. Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School.

Enrique Diloné Ph.D., RAC

Senior Vice President, Technical Operations

Enrique Diloné joined Amicus in August 2009 and currently serves as Senior Vice President, Technical Operations. He brings experience in drug development. Prior to joining Amicus, Dr. Diloné served as Executive Director of Quality and Analytics at NovaDel Pharma Inc., a specialty pharmaceutical company developing oral spray formulations, from February 2007 to August 2009. He served as Senior Director/Director of Analytical Operations at OSI/Eyetech Pharmaceuticals from February 2002 to December 2006. He also worked in several pharmaceutical development departments at Wyeth and Hoffmann-La Roche.

Dr. Diloné received a B.A. in Chemistry from New York University, and a Ph.D. and a M.S., both in Chemistry, from Seton Hall University. He graduated from Harvard Business School’s General Management Program in 2013, and is certified in U.S. Regulatory Affairs.

Hung Do Ph.D.

Chief Science Officer

Hung Do joined Amicus in December 2013 and currently serves as Chief Scientific Officer. Dr. Do brings experience in the field of lysosomal storage diseases (LSDs) and enzyme replacement therapies (ERTs). Prior to joining Amicus, Dr. Do was a Co-founder and Chief Scientific Officer of Callidus Biopharma, a privately-held biologics company that was acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to demonstrate proof-of-concept for ERTs, and served as the project leader for a second-generation Pompe ERT at Genzyme. Dr. Do also led molecular biology, cell culture and purification work and helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme, which was acquired by Genzyme.

Dr. Do holds a Ph.D. in medical biochemistry and genetics from Texas A&M University (mentored by Professor Arthur E. Johnson) and was a post-doctoral fellow in Hematology/Oncology at Emory University (Dr. John S. Lollar). Dr. Do utilizes his focused training in protein synthesis, folding & trafficking to develop better targeted therapeutic treatments for genetic diseases.

Jay A. Barth M.D.

Chief Medical Officer

Jay A. Barth joined Amicus Therapeutics in March 2014 as Chief Medical Officer. Dr. Barth brings experience in drug development, clinical research and medical affairs. Prior joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics, Inc. from 2009 to 2014. He most recently served as PTC’s Senior Vice President, Clinical Development. In this role he led the clinical team and oversaw all global clinical development programs, focusing on rare diseases including Duchenne Muscular Dystrophy and Cystic Fibrosis. Previously Dr. Barth served as Executive Director of Clinical Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical Research Inc.

Dr. Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School of Medicine. He is a member of the American Gastroenterological Association, the American College of Gastroenterology, and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. He is also the author of numerous publications in the fields of medicine and clinical research.

Jayne C. Gershkowitz

Chief Patient Advocate

Jayne C. Gershkowitz joined Amicus in June 2006 and currently serves as Chief Patient Advocate. She is a long-time patient advocacy professional with expertise in the rare disease community, specifically in the LSD space. Prior to joining Amicus, Ms. Gershkowitz served as Executive Director at the NTSAD Association, where she co-founded the LSD Research Consortium in partnership with the National Institute of Neurological Disorders and Stroke (NINDS) and established the NTSAD Research Initiative. Her earlier career experience encompasses newspaper journalism; corporate and non-profit marketing communications; and social services.

Ms. Gershkowitz is active in several organizations within the rare disease community as well as the broader biotech arena. She is a Co-founder and Chair of the Patient Advocacy Committee of BioNJ, and Vice President of Education of the Board of Directors of the NTSAD Association. She is currently a member of the Steering Committee of the Healthcare Institute of New Jersey; the Patient Advocacy and Access and Reimbursement Committees of the Corporate Alliance of the Global Genes RARE Project; and the Policy Working Group of the National Organization for Rare Disorders Corporate Council. Ms. Gershkowitz earned a degree in journalism from the the Newhouse School of Public Communications at Syracuse University and studied business administration at the Radcliffe Graduate Seminars Program.

Jeffrey P. Castelli Ph.D.

Senior Vice President, Program Management and Portfolio Planning

Jeffrey P. Castelli joined Amicus in July 2005 and currently serves as Senior Vice President, Program Management and Portfolio Planning. He brings experience in program management, business operations, alliance management, and as a management consultant. Prior to joining Amicus, Dr. Castelli was a Manager at Health Advances LLC and previously served as a Business Development Analyst at Neose Pharmaceuticals Inc.

Dr. Castelli received a B.S. from West Chester University and a Ph.D. from the University of Pennsylvania.

Kurt J.W. Andrews

Senior Vice President, Human Resources

Kurt J.W. Andrews joined Amicus Therapeutics in February of 2016 as Senior Vice President, Human Resources. Mr. Andrew brings experience working in leadership roles at biotechnology and technology companies including business and commercial strategy, implementation of organization-wide goals and strategies, performance management, and compensation planning. Prior to joining Amicus, Mr. Andrews served as Vice President, Human Resources at Valeritas, Inc. Previously Mr. Andrews was Vice President, Human Resources and Administration at PTC Therapeutics, Inc.

Mr. Andrews earned a B.A. and M.A. from The University of Illinois at Urbana-Champaign.

Patrik S. Florencio Esq.

Chief Compliance Officer

Patrik Florencio joined Amicus Therapeutics in August 2015 as Chief Compliance Officer. Prior to Amicus, Mr. Florencio was the Chief Compliance Officer of NPS Pharmaceuticals Inc. Previously he was the Chief Compliance Officer of Sandoz Inc., where he led both corporate compliance and served as corporate security for almost nine years. Prior to joining Sandoz, Mr. Florencio practiced health law at the law firm of Ropes & Gray in New York City, where he counseled pharmaceutical, hospital system, academic medical center, and other healthcare clients on a host of government enforcement, compliance, and regulatory matters.

Mr. Florencio graduated with degrees in common law, civil law, and neuroscience from McGill University in Montreal, Canada.

William D. "Chip" Baird, III

Chief Financial Officer

William D. "Chip" Baird joined Amicus Therapeutics in April 2012 as Chief Financial Officer. He brings experience in finance and strategic planning. Prior to Amicus Mr. Baird held roles of increasing responsibility for over 10 years at PTC Therapeutics, Inc. As Chief Financial Officer of PTC from April 2005 to April 2012, he was responsible for all areas of finance, investor and public relations, human resources, facilities and project management. During his tenure at PTC, he was instrumental in raising over $500 million through a combination of venture capital, non-dilutive grant funding, collaborations with industry-leading pharmaceutical and biotech companies, and debt financings. Previously, Mr. Baird worked at L.E.K. Consulting, a strategy consulting firm, from 1999 to 2002 and at First Union National Bank as a corporate underwriter from 1994 to 1997.

Mr. Baird received a B.S. from Georgetown University's Edmund A. Walsh School of Foreign Service and an M.B.A. in finance from The Wharton School of the University of Pennsylvania.

Donald J. Hayden , Jr.

Lead Independent Director

Donald J. Hayden, Jr. has served as a member of our Board since March 2006 and as Lead Independent Director since February 2010. Mr. Hayden served as Chairman from March 2006 until February 2010 and from September 2006 until March 2007 as Interim President and Chief Executive Officer. From 1981 to 2006, he held several executive positions with Bristol-Myers Squibb Company, most recently serving as Executive Vice President and President, Americas. Mr. Hayden is Senior Advisor to Prospect Venture Partners, a life sciences venture capital firm, since 2006 and is a member of the Board of Directors of Insmed Incorporated, Vitae Pharmaceuticals, Regenexbio and Otsuka (Tokyo).

Mr. Hayden holds a B.A. from Harvard University and an M.B.A. from Indiana University.

Glenn P. Sblendorio

Executive Vice President, Chief Operating Officer and Chief Financial Officer, Ophthotech

Glenn P. Sblendorio has served as a member of our Board since June 2006. Since April 1, 2016, Mr. Sblendorio has served as Executive Vice President, Chief Operating Officer and Chief Financial Officer of Ophthotech Corporation and was a member of the Board of Directors of Ophthotech until March 31, 2016. Prior to Opthotech, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company from March, 2006 through March, 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31, 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also serves as a member of the Boards of Directors of Intercept Pharmaceuticals and NuLens Ltd., a privately held company.

Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University.

Margaret G. McGlynn R.Ph.

Margaret G. McGlynn has served as a member of our Board since October 2009. Ms. McGlynn has served as CEO and President of The International AIDS Vaccine Initiative since July 2011. She previously served as President, Vaccines and Infectious Diseases of Merck & Co., Inc. from 2005 until her retirement in 2009. Ms. McGlynn joined Merck in 1983, and served in a variety of marketing, sales and managed care roles. Currently, Ms. McGlynn serves as a member of the Boards of Directors of Air Products and Chemicals, Inc. and Vertex Pharmaceuticals, Inc. She is also a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.

Ms. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State University of New York at Buffalo.

Michael G. Raab

Chief Executive Officer and Chairman, Ardelyx

Michael G. Raab has served as a member of our Board of Directors since 2004. Mr. Raab has served as President and Chief Executive Officer of Ardelyx, Inc. since March 2009. Mr. Raab previously served as a partner of New Enterprise Associates from June 2002 until December 2008. From 1999 to 2002, he was a Senior Vice President, Therapeutics and General Manager, Renagel® at Genzyme Corporation. Mr. Raab currently serves as a member of the Board of Directors of Ardelyx, Inc.

Mr. Raab holds a B.A. from DePauw University.

Robert Essner

Senior Advisor, The Carlyle Group

Robert Essner has served as a member of the Board since June 2012. Mr. Essner is Senior Advisor to the global healthcare group at The Carlyle Group, a global private equity firm. Mr. Essner retired as Chairman and Chief Executive Officer of Wyeth, now part of Pfizer, in 2008. During his 32-year career in the pharmaceutical industry, he held several prominent leadership positions, including Chairman of the Pharmaceutical Research and Manufacturers Association. Prior to Wyeth, Mr. Essner spent more than a decade in various management positions at Sandoz Pharmaceuticals Corporation and as President of Sandoz Consumer Healthcare Group. Mr. Essner is currently a Director at MassMutual Financial Group (Chairman). Mr. Essner is also an Executive-in-Residence and Adjunct Professor at Columbia Business School, where he teaches courses in healthcare management.

He received a Bachelor's degree from Miami University and a Master's degree from the University of Chicago.

Sol J. Barer Ph.D.

Managing Director, SJ Barer Consulting, LLC

Sol J. Barer, Ph.D., has served as a member of our Board since January 2009. Dr. Barer is the Managing Director of SJ Barer Consulting, LLC. He served as Chairman of Celgene Corporation from January 2011 to June 2011 and as Executive Chairman from June 2010 to January 2011. From January 2006 to June 2010, he served as Chief Executive Officer of Celgene, and also as Chairman beginning in January 2007. He was appointed President of Celgene in 1993 and Chief Operating Officer and director in 1994. He previously served as Senior Vice President, Science and Technology, and Vice President/General Manager, Chiral Products, from 1991 to 1994, and Vice President, Technology, from 1987 to 1991. Dr. Barer serves on the Boards of Directors of Aegerion, InspireMD, Medgenics (Chair), ContraFect (Lead), Teva, and Edge Therapeutics. He has previously served as Commissioner of the NJ Commission on Science and Technology.

Dr. Barer received a Ph.D. in organic chemistry from Rutgers University and a B.S.degree in Chemistry from City University of New York (Brooklyn College).

Ted W. Love M.D.

Board of Directors, Global Blood Therapeutics

Ted W. Love, M.D., has served as a member of the Board since June 2012. From February 2010 to August 2012, Dr. Love served as Executive Vice President and Head of Research and Development of Onyx Pharmaceuticals. From 2001 to 2009, Dr. Love was the President, Chief Executive Officer and Chairman of the Board of Directors of Nuvelo. Before joining Nuvelo in 2001, he served as Senior Vice President of Development at Theravance, Inc. Prior to that, Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of Genentech's Product Development Committee. In addition to Amicus, Dr. Love currently serves on the Board of Directors of Oncothyreon and Global Blood (CEO).

Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.

Craig A. Wheeler

President and Chief Executive Officer, Momenta Pharmaceuticals

Craig A. Wheeler has served as a member of our Board since June 2016. He is currently President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., where he also serves on the board of directors. Mr. Wheeler led Momenta through the launch of its first complex drug products, including the first generic versions of LOVENOX® and once-daily COPAXONE®. Prior to Momenta, Craig worked at Chiron Corporation as President, Chiron BioPharmaceuticals (now Novartis Vaccines ↦ Diagnostics). Prior to joining Chiron, Craig was a senior member of The Boston Consulting Group's health care practice. Mr. Wheeler also worked for Merck's MSDRL research unit, where he served as a senior engineer in process development and at Hybritech as a financial analyst. Mr. Wheeler previously served for nine years as the Chairman of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. He also served as GPhA’s Chairman of the Board of Directors from 2014 to February 2016.

He holds a BS and an MS degree in chemical engineering from Cornell University, and an MBA from the Wharton School of the University of Pennsylvania.